<DOC>
	<DOCNO>NCT01409876</DOCNO>
	<brief_summary>This phase II trial look feasibility HistoScanning- base dose-painting image- guide interstitial brachytherapy non- metastatic prostate cancer Endpoints : Primary endpoint Evaluation feasibility HistoScanning- base dose-painting image- guide interstitial brachytherapy Secondary endpoints 1 . Evaluating tumor response use HistoScanning 2 . Evaluating locoregional recurrence rate measure PSA 3 . Analysis correlation tumor response determine HistoScanning PSA response 4 . Evaluating safety dose-painting image- guide interstitial brachytherapy record serious adverse event</brief_summary>
	<brief_title>HistScanning- Based PDR Brachytherapy Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy</brief_title>
	<detailed_description>Rationale : The study design prospective monocentric phase II trial . The choice therapeutic concept govern risk group patient fall . Risk group define accord classification D ' Amico . The following concept use : HDR brachytherapy : 19,0- 38 Gy / 2-4 fraction ( 2-4 x 9,5 Gy ) PDR brachytherapy : 35-70 Gy / 50 -- 100 pulse ( 1 puls/h , 24 h/d ) Dose paint timorous area see HistoScanning cover dose Dref2 &gt; 130-150 % External beam radiotherapy use addition brachytherapy intermediate high risk patient . The following concept use 50,40 Gy / 28 fraction 1.8 Gy</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate cancer All cT13 carcinomas independent grade PSA value Prostate volume &lt; 70cc No distant metastasis Karnofsky &gt; 60 Written informed consent patient regard study participation Exclusion criterion : All patient meet inclusion criterion T4 carcinomas Proven metastasis N+ and/or M1 Epidural general anaesthesia possible Pathological clotting parameter</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>histoscanning</keyword>
	<keyword>brachytherapy</keyword>
</DOC>